TARGEPEUTICS

The majority of current cancer therapies kill tumor cells but also kill normal cells, creating unwanted toxicities and side effects. As a biopharmaceutical company, we have found a targeted way to attack only tumor cells. GB-13 is the lead compound in this new direction... To achieve these goals, we are seeking additional equity investments to advance GB-13 into first-in-human Phase I clinical trials... We are taking our first drug, GB-13 to the clinic to deliver RESULTS to patients and their families.

Also known as: Targepeutics, Inc.

Primary location: Hummelstown United States